ArticleBioMed research international2015
Characterization of Multidrug Resistant Extended-Spectrum Beta-Lactamase-Producing Escherichia coli among Uropathogens of Pediatrics in North of Iran.
Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Extended-spectrum beta-lactam-resistant Klebsiella pneumoniae in sub-Saharan Africa: a systematic review and meta-analysis from a One Health perspective.BMC infectious diseases · 2025Pooled it
- Antimicrobial Resistance in Gram-Negative Bacterial Pneumonia After the COVID-19 Pandemic in Northern Iran.Advanced biomedical research · 2025Article
- High prevalence of antimicrobial resistance genes in multidrug-resistant-ESBLs-producingIranian journal of microbiology · 2024Article
- Phenotypic characterization of ESBL-producing urinary isolates of E. coli and Klebsiella spp. in a tertiary care children's hospital in Nepal.Tropical medicine and health · 2024Article
- Prevalence of extended-spectrum beta-lactamase and molecular detection of blaTEM, blaSHV, and blaCTX-M genotypes among gram-negative Bacilli isolates from hospital acquired infections in pediatrics, one institutional study.Italian journal of pediatrics · 2024Article
- High Prevalence of Antimicrobial Resistance Genes in Multidrug-Resistant Extended-Spectrum Beta-Lactamase-ProducingAdvanced biomedical research · 2024Article
- Updating the Antimicrobial Resistance Pattern among Critical Priority Pathogens in the Intensive Care Unit in Northern Iran Post COVID-19 Pandemic.Advanced biomedical research · 2024Article
- Molecular Characterization of Extended Spectrum β-Lactamase ProducingJournal of laboratory physicians · 2023Article
- Molecular epidemiology of antibiotic-resistantIranian journal of microbiology · 2023Article
- Prevalence of extended spectrum beta lactamase and molecular detection of blaTEM, blaSHV and blaCTX-M genotypes among Gram negative bacilli isolates from pediatric patient population in Gaza strip.BMC infectious diseases · 2023Article
- Gut colonization and subsequent infection of neonates caused by extended-spectrum beta-lactamase-producingFrontiers in cellular and infection microbiology · 2023Article
- Molecular Characterization of Extended Spectrum β-Lactamase (ESBL) and Virulence Gene-Factors in UropathogenicAntibiotics (Basel, Switzerland) · 2022Article
- Retrospective Analysis of Antimicrobial Susceptibility of Uropathogens Isolated from Pediatric Patients in Tertiary Hospital at Al-Baha Region, Saudi Arabia.Healthcare (Basel, Switzerland) · 2021Article
- The magnitude of extended-spectrum beta-lactamase- producingAccess microbiology · 2021Review
- Antibiotic Susceptibility and Molecular Characterization of UropathogenicTropical medicine and infectious disease · 2020Article
- Characterization of β-lactam resistance in K. pneumoniae associated with ready-to-eat processed meat in Egypt.PloS one · 2020Article
- Antibiotic Resistance Among UropathogenicPolish journal of microbiology · 2019Review
- Genotypic validation of extended-spectrum β-lactamase and virulence factors in multidrug resistancePathogens and global health · 2019Article
- Molecular Characterization of Extended-Spectrum β-LactamaseThe American journal of tropical medicine and hygiene · 2019Article
- Understanding the Epidemiology of Multi-Drug Resistant Gram-Negative Bacilli in the Middle East Using a One Health Approach.Frontiers in microbiology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli remains as one of the most important bacteria causing infections in pediatrics and producing extended-spectrum beta-lactamases (ESBLs) making them resistant to beta-lactam antibiotics. In this study we aimed to genotype ESBL-producing E. coli isolates from pediatric patients for ESBL genes and determine their association with antimicrobial resistance. One hundred of the E. coli isolates were initially considered ESBL producing based on their MIC results. These isolates were then tested by polymerase chain reaction (PCR) for the presence or absence of CTX, TEM, SHV, GES, and VEB beta-lactamase genes. About 30.5% of isolated E. coli was ESBL-producing strain. The TEM gene was the most prevalent (49%) followed by SHV (44%), CTX (28%), VEB (8%), and GES (0%) genes. The ESBL-producing E. coli isolates were susceptible to carbapenems (66%) and amikacin (58%) and showed high resistance to cefixime (99%), colistin (82%), and ciprofloxacin (76%). In conclusion, carbapenems were the most effective antibiotics against ESBl-producing E. coli in urinary tract infection in North of Iran. The most prevalent gene is the TEM-type, but the other resistant genes and their antimicrobial resistance are on the rise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.